title: Profile of oab patient on treatment with flexible-dose antimuscarinic drugs in daily clinical practice.
abstract: OBJECTIVE
  To describe the profile of the overactive bladder (OAB) patient on treatment with flexible-dose antimuscarinic treatment in daily clinical practice.
  
  
  METHODS
  This was an observational, retrospective and multicenter study, carried out at 88 public and private hospitals. Adult patients diagnosed with OAB who initiated flexible-dose antimuscarinic treatment. Type of antimuscarinic, dose, concomitant treatments, treatment benefit and treatment adherence were recorded.
  
  
  RESULTS
  This was a pluripathological (83.5% and polymedicated 73.4%) population, comprised of 846 patients, mostly women (74.5%) with a mean (SD) age of 61.3 (12.1) years and more than one year of OAB evolution. Main initially prescribed antimuscarinics were fesoterodine (66.5%) and solifenacine (30.0%). Overall, 68.2% of the patients started treatment with the low dosage; at the follow-up visit 47.0% changed the dosage (84.2% increased the dosage, 15.8% decreased the dosage). Patients who changed the dosage showed a significantly greater morbidity, worse OAB symptoms, greater health resources use, and worse adherence to treatment compared with those that maintained the high dosage all the time.
  
  
  CONCLUSIONS
  No differences were found regarding the demographic or clinical characteristics that allow us to identify which patients should receive the different options of available dose of antimuscarinic drugs, although greater benefits seem to be achieved with the use of the highest or the lowest dose from the outset than with the change of dose.
authors.affiliation: Departamento de Urología. Unidad de Suelo Pélvico Consorcio Hospital General Universitario de Valencia. Valencia. España.
authors.forename: Francisco
authors.initials: F
authors.lastname: Sánchez-Ballester
authors.affiliation: Departamento de Urología. MD Anderson. Madrid.España.
authors.forename: Jose María
authors.initials: JM
authors.lastname: García-Mediero
authors.affiliation: Departamento de Urología. Consorcio Hospital General Universitario de Valencia. España.
authors.forename: Marcos
authors.initials: M
authors.lastname: Sobrón-Bustamante
authors.affiliation: Departamento Medico. Pfizer Inc. Europe. Alcobendas. Madrid. España.
authors.forename: Isabel
authors.initials: I
authors.lastname: Lizarraga
authors.affiliation: Departamento Medico. Pfizer Inc. Europe. Alcobendas. Madrid. España.
authors.forename: Daniel
authors.initials: D
authors.lastname: Arumi
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D012189:Retrospective Studies; D000069464:Solifenacin Succinate / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D001559:Benzhydryl Compounds; D018727:Muscarinic Antagonists; C526675:fesoterodine; D000069464:Solifenacin Succinate